

## CLAIMS

In the claims, kindly amend as follows:

1. (currently amended) A vector for the surface expression of ~~antibiotic~~antibiotics, which comprises:  
one or more than two genes selected from the group consisting of pgsB, pgsC and pgsA, said genes encoding a poly-gamma-glutamate synthetase complex; and  
a gene encoding P5 an amphiphilic peptide antibiotics with antibacterial, antifungal and anticancer activities, wherein P5 peptide is encoded by the base sequence of SEQ ID NO: 4.
2. (original) The vector according to claim 1, wherein said pgsB, pgsC and pgsA genes have the base sequences described in SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, respectively.
3. (original) The vector according to claim 1, wherein the vector contains the pgsA gene among the genes encoding the poly-gamma-glutamate synthetase complex.
4. (canceled)
5. (currently amended) ~~A~~The vector according to claim 1, said vector is pHCE1LB:pgsA-P5 for the surface expression of ~~antibiotic~~antibiotics, which expresses said antibioticantibiotics on the surface of gram-negative and gram-positive bacteria.
6. (currently amended) A microorganism transformed with the vector of claim ~~1~~4.
7. (original) *E. coli* (KCTC 10350BP) transformed with the vector pHCE1LB:pgsA-P5 of claim 5.
8. (currently amended) A lactic acid-forming bacteria transformed with the vector of claim ~~1~~4.

9. (canceled)

10. (canceled)

11. (currently amended) A pharmaceutical composition and suspension of the same for antibacterial, antifungal or anticancer application, which comprises, as an active ingredient, the lactic acid-forming bacteria according to claim 8 ~~produced by the method of claim 10~~ and having the peptide ~~antibiotic~~antibiotics P5 expressed on their surface.

12. (original) The pharmaceutical composition according to claim 11, wherein said active ingredient is heat-treated.

13-22. (canceled)